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S U M M A R Y
Background: Tuberculosis remains a public health problem in France and the diagnosis of tuberculosis
disease (TB) is sometimes difﬁcult. The aim of this study was to analyse the contribution of the
QuantiFERON-TB Gold In-Tube assay (QFT-GIT) to TB diagnosis.
Methods: Sixty patients hospitalized with TB, for whom a QFT-GIT assay had been performed between
June 2008 and June 2011 at the University Hospital of Bondy in the north-east of Paris, were identiﬁed
retrospectively. Clinical and laboratory data were collected. The sensitivity, speciﬁcity, predictive values,
and likelihood ratios of the QFT-GIT were all calculated. Furthermore, the characteristics of patients
testing positive were compared to those of patients testing negative, as well as the QFT-GIT values
according to several different factors.
Results: The sensitivity of the QFT-GIT was 85% (95% conﬁdence interval (CI) 0.73–0.92) and speciﬁcity was
73.3% (95% CI 0.68–0.78). The positive predictive value was 39.5% and the negative predictive value was
97.3%. The positive and negative likelihood ratios were 3.2 and 0.20, respectively. The prevalence of TB in
this population was 15% (pre-test probability). After a positive test result, the probability of TB increased to
40% (post-positive probability test); after a negative test result, it decreased to 4.5% (post-negative
probability test). The combination of the QFT-GIT test with the tuberculin skin test brought no signiﬁcant
improvement in sensitivity. Factors signiﬁcantly associated with a negative QFT-GIT result included older
age, high C-reactive protein, a low lymphocyte count, and immunosuppressant intake. The test value in
quantitative terms was signiﬁcantly higher in those with lymph node TB than in those with pulmonary TB,
and in younger patients (<40 years) than in older patients (>40 years old).
Conclusion: Onits own, QFT-GIT isan insufﬁcienttool to conﬁrm thediagnosis of TB disease. However, it may
form part of an ensemble of tools in combination with clinical, biological, and radiological assessments.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Tuberculosis (TB) is a major public health problem that affects a
third of the world’s population and remains the biggest cause of
mortality and morbidity through infection.1 In France, 4975 cases
of TB disease were reported to the health authorities in 2012, or
7.6 cases per 100 000 inhabitants. Compared with other parts of
the world, this incidence is low, but inter-regional disparities exist.
The French administrative area of Seine Saint Denis in the* Corresponding author. Tel.: +33 1 48 95 54 55.
E-mail address: mohammed.azghay@avc.aphp.fr (M. Azghay).
http://dx.doi.org/10.1016/j.ijid.2016.01.004
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).north-east of Paris has one of the highest rates of reported TB in
France, with 28 cases per 100 000 inhabitants in 2012.2
The tuberculin skin test (TST) has many disadvantages,
including many false-positive results in the population vaccinated
with bacille Calmette–Gue´rin (BCG) and in patients infected with
atypical mycobacteria. Furthermore, it provides many false-
negative results in the elderly and in immunocompromised
populations (e.g., people living with HIV).3
The GeneXpert PCR technique ﬁrst became available only a few
years ago. This allows the early detection of Mycobacterium
tuberculosis complex and the detection of multidrug-resistant TB.4
Its sensitivity varies depending on the origin of the sample and the
bacterial load.5ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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release of interferon-gamma (IFN-g) by lymphocytes in contact
with synthetic peptides speciﬁc to M. tuberculosis. In France, their
use in the diagnosis of latent TB, in place of the TST, is now
recommended by the French National Authority for Health and the
High Committee on Public Health.6 However, contradictory results
with respect to their use in the diagnosis of TB has been highlighted
in many studies, thus doctors are reluctant to prescribe them.7,8
The aim of this study was to analyse the performance of the
QuantiFERON-TB Gold In-Tube assay (QFT-GIT) in the diagnosis of
TB disease using retrospective data obtained from patients with
pulmonary or extrapulmonary TB, who were hospitalized in Seine
Sainte Denis, a French administrative region with a high TB
prevalence.
2. Patients and methods
2.1. Study population
A retrospective study was performed on all adult patients
hospitalized for suspected pulmonary or extrapulmonary TB for
whom a QFT-GIT assay had been performed in the internal
medicine department of the Jean Verdier Hospital in Bondy
(district of Seine Saint Denis) between June 1, 2008 and June 30,
2011. Patients who had undergone QFT-GIT screening for latent TB
before the initiation of immunosuppressive therapy or chemo-
therapy were excluded.
2.2. Deﬁnitions and diagnosis
A ‘certain’ diagnosis of TB was based either on bacteriological
evidence (direct examination or culture) or histological evidence
(identiﬁcation of epithelioid giant cell granuloma with caseous
necrosis). A ‘probable’ diagnosis was based on clinical, biological,
and radiological ﬁndings and a favourable TB treatment response.
Each diagnosis was reviewed retrospectively. The QFT-GIT was not
one of the diagnostic criteria. The diagnosis was rejected when the
clinical, biological, and radiological data did not sufﬁciently
validate the need to begin TB treatment, or when a non-favourable
disease response while on treatment was observed.
Direct bacteriological examination and culture were performed
on sputum or gastric tube samples and/or puncture/organ biopsy
samples. Direct examination (Ziehl–Nielsen method) and culture
(solid Lowenstein medium and/or liquid culture for positive direct
examination or puncture/organ biopsy) were performed in the
mycobacterial laboratory of the Jean Verdier Hospital. Identiﬁca-
tion of the strain and susceptibility testing were performed when
the culture was positive. Histological examination of organ
biopsies was performed in the pathology laboratory of the Jean
Verdier Hospital.
2.3. Data collection
The following data were collected: age, sex, immunosuppres-
sive factors (diabetes, chronic renal failure, progressive cancer,
immunosuppressive therapy in the previous 3 months), and
biological data (lymphocyte cell count, HIV, hepatitis B virus, and
hepatitis C virus status, gammaglobulinemia, albumin, lactate
dehydrogenase (LDH), C-reactive protein (CRP)). Data were also
collected on the type of TB (pulmonary, pleural, lymph node, bone,
peritoneal, liver, urinary tract, uterine, neuromeningeal, miliary, or
other) and means of diagnosis.
The study was approved by the Paris Nord University
Institutional Review Board (Comite´ de Protection des Personnes
de Paris-Iˆle de France).2.4. QuantiFERON-Gold In-Tube assay (QFT-GIT)
All QFT-GIT assays on heparinized venous blood samples taken
at the Jean Verdier Hospital during the period 2008–2011 were
performed by the Autoimmunity and Hypersensitivities Unit at the
University Hospital Bichat-Claude Bernard (QuantiFERON-Gold In-
Tube; Qiagen, buyer of Australian biotechnology ﬁrm Cellestis).
Three heparin tubes were collected: (1) negative control tube (NIL
tube), (2) antigen tube (AG tube; contained a coating of speciﬁc
antigens of M. tuberculosis (ESAT-6, CFP-10, TB 7.7), which came
into contact with the patient’s T-cells in the blood sample), and (3)
positive control tube containing phytohaemagglutinin-P (PHA)
(MIT tube). The concentration of IFN-g secreted by the cells was
measured by ELISA. The results were measured in IU/ml and
interpreted in accordance with the manufacturer’s recommenda-
tions as negative, positive, or indeterminate.
2.5. Tuberculin skin test (TST)
TSTs were performed in the unit using the Mantoux method,
with 1 U of tuberculin (Tubertest; Sanoﬁ Pasteur MSD). The result
was read at 72 h. A positive test suggested active TB disease or
latent TB infection. A cut-off of 10 mm of induration was used to
deﬁne a positive TST in adult BCG-vaccinated or non-vaccinated
subjects.9 In people living with HIV infection, a cut-off of 5 mm of
induration was considered a positive test result.10 If there was a
skin blister, this was interpreted as suggestive of infection. The TST
was always performed after blood samples had been drawn for the
QFT-GIT assay. A group of patients who had received both the TST
and QFT-GIT (‘combined test’ group) was created. The result of the
combined test was considered positive if either of the two tests
was positive, and negative if both tests were negative.
2.6. Statistical analysis
The sensitivity, speciﬁcity, and predictive values were calculat-
ed for the QFT-GIT. Two speciﬁcity calculations were done, one
including patients with ‘indeterminate’ results and the other not
including them. The Wilson test was used to calculate 95%
conﬁdence intervals (CI). The positive and negative likelihood
ratios were also calculated for the QFT-GIT test, having the
advantage of being independent of the prevalence of the disease in
the population.
Patient characteristics were expressed as the number (%) or as
the median (standard deviation (SD)) and were compared between
the QFT-GIT-positive group and the combined QFT-GIT-negative/
indeterminate group. The Mann–Whitney–Wilcoxon test was used
to compare quantitative variables, while Fisher’s test was used for
qualitative variables. A multivariate analysis was not performed,
given the low number of patients with TB.
Finally, quantitative values of QFT-GIT were compared for those
variables that were signiﬁcantly different in the univariate analysis
(age and total lymphocyte count) and between the different TB
sites (pulmonary vs. lymph node, patients with both TB sites being
classiﬁed in both groups).
3. Results
3.1. Clinical characteristics
A total of 790 QFT-GIT assays were performed, of which 395
(50%) were done for suspected TB disease (Figure 1): 60 (15.2%) of
these patients had TB and received treatment, while 335 (74.8%)
did not have TB and were not treated. Half of the patients for whom
a QFT-GIT assay was performed were excluded: 297 prior to the
initiation of immunosuppressive therapy and 98 for various
Figure 1. Flow chart of the study population.
Table 1
Characteristics of patients with active tuberculosis, patients with a positive QFT-GIT, a
Characteristics Active TB
(n = 60)
QFT
(n =
Male/female 35/25 29/2
Age, years, median (SD) 36 (18.75) 35 
Region of origin
Maghreb 20
Sub-Saharan Africa 13
Europe 11
Haiti 7
Asia 4
Other 5
Type of TB
Pulmonary 19 15 
Extrapulmonary 41 36 
HIVd
Positive 5 4 
Negative 55 44 
Immunosuppressive drugs 3/60 0 
Cancer 2/60
Diabetes 5/60
Chronic renal failure 0/60
Lymphocyte count, 109/l
>1.5 34/60 32 
<1.5 26/60 19 
Median 1.680 1.79
Albumin, g/l, median 35.85 36.3
Gamma globulin, median (SD) 15.1 (6.33) 15.2
LDH, IU, median 423 411
CRP, mg/l, median 24 23 
Microbiology, n
Direct examination positive 16 13 
Culture positive 39 34 
Direct examination negative/culture positive 23 21 
Histology, n
Positive 25/42 23/3
Negative 17/42 14/3
Certain diagnosise, n 45 39 
Probable diagnosisf, n 15 12 
Tuberculin skin test
Positive 21/27 19/2
Negative 6/27 4/23
QFT-GIT, QuantiFERON-TB Gold In-Tube assay; TB, tuberculosis; SD, standard deviation
a Three patients with an indeterminate QFT-GIT are included in this group.
b p-Value for the difference between the QFT-GIT-positive group and the QFT-GIT-n
c Signiﬁcant at p < 0.05.
d One patient had an unknown HIV status.
e Certain diagnosis: positive culture and/or positive histology.
f Probable diagnosis: negative culture and negative histology.
M. Azghay et al. / International Journal of Infectious Diseases 44 (2016) 25–30 27reasons (HIV infection, granulomatosis, sickle cell disease,
suspected latent TB).
The characteristics of the patients with TB (n = 60) are
summarized in Table 1. The male to female sex ratio was 1.4,
mean age (SD) was 36 (18.75) years, and only 11 cases were of
European origin (18.3%), including ﬁve from Eastern Europe.
Nineteen patients (31%) had isolated pulmonary TB, while 41 (69%)
had extrapulmonary TB, including 20 cases of isolated lymph node
TB, three cases of hepatic TB, three cases of spondylodiscitis, two
cases of miliary TB, three cases of isolated pleural involvement, two
cases of peritoneal localization, one of whom had associated
pleural involvement, one case with uterine TB, and seven patients
with multiple-site TB. Five patients were HIV-positive (recent
diagnosis for two of them, all with a CD4 count >200 cells/mm3).
Three patients were on the following immunomodulators at
diagnosis: hydroxyurea, sulfasalazine, and inﬂiximab. Two
patients had neoplastic disease (mucinous ovarian tumour,
gastrointestinal leiomyosarcoma). Forty-ﬁve patients (75%) had
a deﬁnite diagnosis, based on bacteriological and/or histological
data, and 15 patients (25%) had a probable diagnosis. Twenty-three
patients had a negative result after direct bacteriological testing
and a positive result from culture (Table 1).nd patients with a negative or indeterminate QFT-GIT
-GIT-positive
 51)
QFT-GIT-negative/ indeterminatea
(n = 9)
p-Valueb
2 6/3 0.582
63 0.005c
4 0.443
5
1 0.702
7
3 (QFT-GIT-negative) <0.0001c
2
7 0.017c
0 1.200
5 32.1 0.19
 (6.29) 12.8 (6.79) 0.483
 485 0.195
75 0.009c
3 0.822
5 0.238
2
7 2/5
7 3/5 0.343
6
3 0.531
3 2/4
 2/4 0.148
; LDH, lactate dehydrogenase; CRP, C-reactive protein.
egative group.
Table 2
Distribution of QFT-GIT results according to the diagnosis of tuberculosis—conﬁrmed or dismissed
Tuberculosis QFT-GIT-positive, n (%) QFT-GIT-negative, n (%) QFT-GIT not interpretable, n (%) Total, n
TB diagnosis conﬁrmed 51 (85%) 6 (10%) 3 (5%) 60
TB diagnosis dismissed 78 (23.3%) 214 (63.9%) 43 (12.8%) 335
Total 129 (32.7%) 220 (55.7%) 46 (11.6%) 395
QFT-GIT, QuantiFERON-TB Gold In-Tube assay; TB, tuberculosis.
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Of the 60 patients who had been tested for TB, 51 (85%) had a
positive QFT-GIT result, three (5%) had an uninterpretable result,
and six (10%) had a negative result. Among the 335 patients for
whom a TB diagnosis was initially suspected but eventually
rejected, 78 (23.3%) had a positive QFT-GIT result, 43 (12.8%) had
an uninterpretable result, and 214 (63.9%) had a negative result
(Table 2). The sensitivity of QFT-GIT for TB diagnosis was 85% (95%
CI 0.73–0.92) and the speciﬁcity 64% (95% CI 0.58–0.69) when the
indeterminate and negative results were combined.
When the indeterminate results were excluded, speciﬁcity
increased to 73.3% (95% CI 0.68–0.78), the positive predictive value
was 39.5%, the negative predictive value was 97.3%, the positive
likelihood ratio was 3.2, and the negative likelihood ratio was
0.20. With a prevalence of 15% in the population (61/395), a
positive test increased the likelihood of having the disease to 40%,
while a negative test decreased it to 4.5%. The TST was performed
on 27 patients and was positive in 21 patients, giving a sensitivity
of 78% (95% CI 0.57–0.91). The sensitivity of the ‘combined test’
(n = 27) was 92.6% (95% CI 0.74–0.99).
Sensitivity in the group of patients with a certain diagnosis
(positive microbiology and/or typical histology) was 86.7% (95% CI
0.74–0.94), whereas the sensitivity in the patient group with a
probable diagnosis was 80% (95% CI 0.55–0.93). In the group with a
negative direct microbiological result but with positive culture
(n = 23; included in some diagnoses), sensitivity was 91.3% (95% CI
0.73–0.98) (Table 3).
3.3. Comparison of patient characteristics according to the QFT-GIT
result
Table 1 shows the patient characteristics compared according
to the QFT-GIT results (positive versus negative or indeterminate).
Age was signiﬁcantly higher in the group with a negative QFT-GIT
compared to the group with a positive QFT-GIT (63 (SD 24.9) years
vs. 35 (SD 16.2) years; p = 0.005). The total lymphocyte count wasTable 3
Diagnostic performance of QFT-GIT
Sensitivity of QFT-GIT 85% (0.73–0.92)
Speciﬁcity of QFT-GIT
(with indeterminate results)
64% (0.58–0.69)
Speciﬁcity of QFT-GIT
(without indeterminate
results being included in the
negative results)
73.3% (0.68–0.78)
Positive predictive value 39.5%
Negative predictive value 97.3%
Positive likelihood ratio 3.20
Negative likelihood ratio 0.20
TST sensitivity 78% (0.57–0.9)
QFT-GIT + TST group sensitivity 92.6% (0.74–0.99)
Certain diagnosis group sensitivity
(45 patients)
86.7% (0.74–0.94)
Probable diagnosis group sensitivity
(15 patients)
80% (0.55–0.93)
Direct examination negative/culture
positive microbiology group sensitivity (23 patients)
91.3% (0.73–0.98)
QFT-GIT, QuantiFERON-TB Gold In-Tube assay; TST, tuberculin skin test.lower in the QFT-GIT-negative group than in the QFT-GIT-positive
group (median 1.200 vs. 1.790  109 cells/l; p = 0.017). CRP was
higher in the QFT-GIT-negative group (75 mg/l vs. 23 mg/l;
p = 0.009). Finally, all patients taking immunosuppressants had a
negative QFT-GIT (3 patients vs. 0 patients; p < 0.0001).
Other characteristics were not signiﬁcantly different between
the two groups.
3.4. Study of the quantitative results of QFT-GIT
The quantitative QFT-GIT values were signiﬁcantly higher
(p = 0.03) in the 24 patients with lymph node involvement (median
QFT-GIT of 8.07 IU/ml) with respect to the 22 patients with lung
disease (median QFT-GIT of 2.15 IU/ml) (Figure 2A). QFT-GIT
values were signiﬁcantly higher (p = 0.005) in patients under
40 years of age (median QFT-GIT of 4.84 IU/ml) compared to those
over 40 years old (median QFT-GIT of 1.94 IU/ml) (Figure 2B).
4. Discussion
In France, a very high percentage of TB sufferers are of foreign
origin;11 in the present study only ﬁve of the 60 patients were born
in Western Europe. Other characteristics, however, were broadly
comparable between patients.
The sensitivity value obtained in this study (85%, 95% CI 0.73–
0.92) is comparable to those reported in the main meta-analyses
performed to date: Diel et al.7 found a sensitivity of 81%, while
Sester et al.8 found a sensitivity of 80%. In the present study, the
sensitivity increased to 92.6% (95% CI 0.74–0.99) when using the
combined QFT-GIT and TST test. Of the 27 patients with a TST and
QFT-GIT, only two had a positive TST and a false-negative QFT-GIT.
One of these patients had a certain diagnosis of TB and the other a
probable diagnosis. The advantage of using both tests together is
quite low. Moreover, the QFT-GIT sensitivity in the present study
cohort (85%, 95% CI 0.73–0.92) did not increase signiﬁcantly in
either the group of patients with a certain diagnosis (86.7%, 95% CI
0.74–0.94) or in the group with a negative direct examination and
positive culture (91.3%, 95% CI 0.73–0.98).
The speciﬁcity was lower (73%) in the present study than those
found in the meta-analyses by Diel et al. (99.2%) and Sester et al.
(79%). This can be explained by the fact that latent TB in the study
region is high, and therefore the risk of patients with no TB disease
having a positive QFT-GIT is greater, since this test does not
distinguish between the two forms of TB (active and latent).
In the present study, the positive and negative likelihood ratios
were 3.2 and 0.2, respectively. The positive likelihood ratio in the
meta-analysis of Diel et al.7 was 101 and in the meta-analysis of
Sester et al.8 was 3.81, while the negative likelihood ratios were
0.191 and 0.25, respectively. The results of the present study are
therefore comparable with those of Sester et al. The difference
between the two meta-analyses can be explained by the fact that
Diel et al. selected only ﬁve studies with patients who had a very
low risk of illness: for the 513 patients selected, the QFT-GIT was
positive in only four. QFT-GIT speciﬁcity was overestimated at
99.2% (95% CI 0.98–1.00), resulting in an artiﬁcial increase in the
positive likelihood ratio.
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Figure 2. Boxplot of QTF rates according to (A) type of tuberculosis, (B) age.
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et al. analysed the performance of microbiological examination of
sputum to detect TB. That meta-analysis included 7771 patients.
The sensitivity of direct examination of sputum was 64% and
speciﬁcity was 68%. The positive and negative likelihood ratios
were 30 and 0.37, respectively. Direct examination of sputum was
therefore much more informative than the QFT-GIT when positive,
but less effective when negative.12
As highlighted in the literature, elderly age,13,14 a low level of
total lymphocytes,15 and taking immunosuppressants16 are three
factors that increase the risk of a false-negative QFT-GIT. In the
present study a signiﬁcantly higher CRP result was also found in
the negative QFT-GIT group, which may be explained by a possible
associated bacterial co-infection leading to a negative QFT-GIT
result. This suggestion was made in a South Korean study involving
168 patients that was published in 2013.17Previous studies on the quantitative values of QFT-GIT have
shown either higher levels in patients with active TB when
compared to those with latent TB,18 or stable19 or decreasing20
values for patients on treatment for TB. In the present study, the
QFT-GIT values were found to be signiﬁcantly higher in patients
with lymph node TB than in those with pulmonary TB. This result is
interesting, as it is speciﬁcally extrapulmonary TB that is linked to
difﬁcult diagnosis. This is because of the invasive procedures that
are often necessary to obtain bacteriological or histological proof,21
and also because of the low sensitivity of the tests used (e.g.,
GeneXpert). In addition, several weeks may be needed for culture
results. Furthermore, histology/radiography results often do not
provide any further information regarding diagnosis.22
A high QFT-GIT level may be of interesting diagnostic value in
lymph node TB. This appears to be conﬁrmed by Kyoung-Ho Song
et al. who found a QFT-GIT sensitivity of 86% (95% CI 0.64–0.97).
M. Azghay et al. / International Journal of Infectious Diseases 44 (2016) 25–3030However, these results cannot necessarily be extrapolated to other
forms of extrapulmonary TB, such as osseous TB, for which a
sensitivity of only 45% (95% CI 0.17–0.77) has been found.23
This study had several limitations: (1) there was a high rate of
extrapulmonary TB (68.3%), mainly lymph node, whereas this rate is
around 30% over the entire French territory, probably because many
cases of pulmonary TB did not need a QFT-GIT assay for diagnosis; (2)
the number of HIV patients was low and therefore it was not possible
to perform a relevant statistical analysis on this population or to
extrapolate the results to HIV patients in general, for whom the QFT-
GIT is recommended by national health authorities; (3) speciﬁcity
was probably underestimated because it was calculated on patients
with a high prevalence of latent TB; and ﬁnally (4) this was a
retrospective observational study in which QFT-GIT was not
prescribed systematically, especially for those with a clear diagnosis.
In conclusion, the QFT-GIT assay should not be recommended
routinely for the diagnosis of TB as the positive and negative
likelihood ratios, 3.2 and 0.2 respectively, are of mediocre value.
The assay may also produce false-negative results in some
situations: elderly age, high CRP, low total lymphocyte count, or
when immunosuppressants are being taken. However, the QFT-GIT
may be used as an element in the diagnosis of TB in certain
situations, particularly for lymph node TB (where the QFT-GIT level
is higher) and in low incidence areas (to limit the number of
patients with latent TB).
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